… n patients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min). In these patients Candesartan Cilexetil should be carefully titrated with thorough monitoring of blood pressure.
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of Candesartan Cilexetil, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine > 265 µmol/l (> 3 mg/dl).
Paediatric population, including paediatric patients with renal impairment
Candesartan Cilexetil has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73m2 (s …
Identical in all 3 labels. Surrounding text shown from Aurobindo Pharma - Milpharm Ltd..
… ted experience in patients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min). In these patients Amias should be carefully titrated with thorough monitoring of blood pressure.
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of Amias, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine > 265 µmol/l (> 3 mg/dl).
Use in paediatric patients including patients with renal impairment
Amias has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73m2 (see section 4.2).
Con …
Identical in both labels. Surrounding text shown from Neon Healthcare Ltd.
… atients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min).
In these patients Candesartan cilexetil should be carefully titrated with thorough monitoring of blood pressure.
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of Candesartan cilexetil, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine >265 μmol/L (>3 mg/dl).
Concomitant therapy with an ACE inhibitor in heart failure
The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may …
Identical in both labels. Surrounding text shown from Krka UK Ltd.
… ted experience in patients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min). In these patients Amias should be carefully titrated with thorough monitoring of blood pressure.
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose
titration of Amias, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine > 265 µmol/l (> 3 mg/dl).
Use in p …
… n patients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min). In these patients Candesartan Cilexetil should be carefully titrated with thorough monitoring of blood pressure.
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of Candesartan Cilexetil, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine >265 μmol/l (>3 mg/dl).
Concomitant therapy with an ACE inhibitor in heart failure
The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may …
… xperience in patients with very severe or end-stage renal impairment (Clcreatinine <15 ml/min). In these patients candesartan should be carefully titrated with thorough monitoring of blood pressure.
Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of candesartan, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine >265 μmol/L (>3 mg/dL).
Use in paediatric patients, including patients with renal impairment
Candesartan has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73 m2 (see section 4.2).
…